ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

PHVS Pharvaris NV

22,60
-0,93 (-3,95%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Pharvaris NV PHVS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,93 -3,95% 22,60 23:34:21
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
23,77 22,475 23,90 22,60 23,53
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
10.4.202422:10GLOBEPharvaris Reports Fourth Quarter and Full Year 2023..
10.4.202422:08GLOBEPharvaris Appoints David Nassif, J.D., as Chief Financial..
04.4.202412:50GLOBEPharvaris to Present Deucrictibant Clinical Data at the CIIC..
18.3.202411:50GLOBEPharvaris Announces Phase 3 Clinical Study Design for..
11.3.202418:51EDGAR2Form 144 - Report of proposed sale of securities
06.3.202422:40EDGAR2Form F-3ASR - Automatic shelf registration statement of..
06.3.202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.3.202412:50GLOBEPharvaris to Present Deucrictibant Clinical Data at Upcoming..
05.3.202412:50GLOBEPharvaris to Participate in the Leerink Global Biopharma..
22.2.202412:50GLOBEPositive Results from CHAPTER-1 Phase 2 Study of..
16.2.202412:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16.2.202412:50GLOBEPharvaris Announces Extraordinary Meeting of Shareholders
07.2.202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.2.202422:46EDGAR2Form 144 - Report of proposed sale of securities
26.1.202412:50GLOBEPharvaris to Present at the WSAAI Annual Meeting 2024
22.1.202413:35DJNPharvaris Says FDA Lifted Clinical Hold on Application for..
22.1.202412:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22.1.202412:50GLOBEPharvaris Announces FDA Lifting of the Clinical Hold of..
08.1.202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.1.202412:50GLOBEPharvaris Provides Business Update and Outlines 2024..
02.1.202422:29EDGAR2Form 144 - Report of proposed sale of securities
09.12.202300:00GLOBEPharvaris Presents Deucrictibant Clinical Data and Analysis..
08.12.202322:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.12.202322:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06.12.202322:36EDGAR2Form 144 - Report of proposed sale of securities
06.12.202313:08EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
06.12.202313:02GLOBEPharvaris Announces Pricing of $300 Million Underwritten..
06.12.202312:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.12.202312:50GLOBEPharvaris Announces Positive Top-line Phase 2 Data from the..
30.11.202312:50GLOBEPharvaris to Present at the GA²LEN UCARE Conference 2023
15.11.202312:50GLOBEPharvaris Appoints Stefan Abele, Ph.D., as Chief Technical..
09.11.202317:00GLOBEPharvaris Presents Deucrictibant Clinical Data and..
02.11.202311:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02.11.202311:50GLOBEPharvaris Reports Third Quarter 2023 Financial Results and..
30.10.202311:50GLOBEPharvaris To Present at the ACAAI 2023 Annual Scientific..
13.10.202312:50GLOBEPharvaris To Present at the APAAACI 2023 International..
04.10.202313:34GLOBEPharvaris To Present at the CIIC Fall 2023 Conference
19.9.202322:23EDGAR2Form 144 - Report of proposed sale of securities
19.9.202312:50GLOBEPharvaris To Participate in the 2023 Cantor Global..
06.9.202312:51GLOBEPharvaris To Present at the 18th German Allergy Congress
06.9.202312:50GLOBEPharvaris To Participate in the Morgan Stanley 21st Annual..
02.9.202300:02EDGAR2Form 144 - Report of proposed sale of securities
24.8.202322:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23.8.202312:50GLOBEPharvaris To Present at the 2023 HAEi Regional Conference..
17.8.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
10.8.202301:00EDGAR2Form 144 - Report of proposed sale of securities
10.8.202300:38EDGAR2Form 144 - Report of proposed sale of securities
07.8.202316:16EDGAR2Form F-3 - Registration statement by foreign private issuers
07.8.202312:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.8.202312:50GLOBEPharvaris Reports Second Quarter 2023 Financial Results and..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock